XBIT

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

 

 

 

XBIOTECH INC.

(Name of Issuer)

Common Shares, no par value

(Title of Class of Securities)

98400H102

(CUSIP Number)

December 31, 2022

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

[_] Rule 13d-1(b)

 

[ ] Rule 13d-1(c)

 

[x] Rule 13d-1(d)

 

¹The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ).

 

SCHEDULE 13G

 

 

CUSIP No.

98400H102

1

Names of Reporting Persons

John Simard

2

Check the appropriate box if a member of a Group (see instructions)

(a)  [ ] (b)  [ ]

3

Sec Use Only

4

Citizenship or Place of Organization

Canada

5

Sole Voting Power

5,193,547 (1)

Number of Shares

6

Shared Voting Power

Beneficially Owned

by Each Reporting

N/A

Person With:

7

Sole Dispositive Power

5,193,547 (1)

8

Shared Dispositive Power

N/A

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,193,547 (1)

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

[ ]

11

Percent of class represented by amount in row (9)

16.33%(2)

12

Type of Reporting Person (See Instructions)

IN

 

	(1)	These figures include shares of common stock underlying stock options held by the Reporting Person, including options which are immediately exercisable within 60 days of December 31, 2022.
	(2)	The percentage is calculated based upon 30,439,275 shares outstanding as of December 31, 2022.

 

 

Item 1.

 

(a)

Name of Issuer:

 

XBiotech Inc.

 

(b)

Address of Issuer’s Principal Executive Offices:

 

5217 Winnebago Ln, Austin, TX 78744

 

Item 2.

 

(a)

Name of Person Filing:

 

John Simard

 

(b)

Address of Principal Business Office or, if None, Residence:

 

5217 Winnebago Ln, Austin, TX 78744

 

(c)

Citizenship:

 

Canada

 

(d)

Title and Class of Securities:

 

Common Shares, no par value

 

(e)

CUSIP No.:

 

98400H102

 

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

Not Applicable

 

Item 4.

Ownership

 

As of December 31, 2022

 

(a)

Amount Beneficially Owned:

 

5,193,547⁽¹⁾ shares

 

(b)

Percent of Class:

 

16.33%⁽²⁾

 

(c)       Number of shares as to which such person has:

 

(i)

Sole power to vote or to direct the vote:

 

5,193,547 ⁽¹⁾ shares

 

(ii)

Shared power to vote or to direct the vote:

 

Not Applicable

 

(iii)

Sole power to dispose or to direct the disposition of:

 

5,193,547 ^{(1 )} shares

 

(iv)

Shared power to dispose or to direct the disposition of:

 

Not Applicable

 

(1)

These figures include shares of common stock underlying stock options held by the Reporting Person, including options which are immediately exercisable within 60 days of December 31, 2022.

 

(2)

The percentage is calculated based upon 30,439,275 shares outstanding as of December 31, 2022.

 

Item 5.

Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

 

Item 6.

Ownership of more than Five Percent on Behalf of Another Person.

 

Not Applicable

 

Item 7.

Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

 

Not Applicable

 

Item 8.

Identification and classification of members of the group.

 

Not Applicable

 

Item 9.

Notice of Dissolution of Group.

 

Not Applicable

 

Item 10.

Certifications.

 

Not Applicable

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 10, 2023

 

/s/ John Simard

 

John Simard/President & CEO, XBiotech Inc.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5 of 5